Trial Profile
A Multicenter Exploratory Study of Paclitaxel+Cisplatin+TQB2450 Injection Combined With or Without Anlotinib in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Benmelstobart (Primary) ; Catequentinib (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary)
- Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 06 Jun 2023 Results (n=45, as of data cut off date of January 16, 2023) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 Status changed from not yet recruiting to recruiting, according to a results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 25 Aug 2021 New trial record